» Articles » PMID: 28341975

Longitudinal Volumetric and 2D Assessment of Cerebellar Atrophy in a Large Cohort of Children with Phosphomannomutase Deficiency (PMM2-CDG)

Overview
Publisher Wiley
Date 2017 Mar 26
PMID 28341975
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: We aim to delineate the progression of cerebellar atrophy (the primary neuroimaging finding) in children with phosphomannomutase-deficiency (PMM2-CDG) by analyzing longitudinal MRI studies and performing cerebellar volumetric analysis and a 2D cerebellar measurement.

Methods: Statistical analysis was used to compare MRI measurements [midsagittal vermis relative diameter (MVRD) and volume] of children with PMM2-CDG and sex- and age-matched controls, and to determine the rate of progression of cerebellar atrophy at different ages.

Results: Fifty MRI studies of 33 PMM2-CDG patients were used for 2D evaluation, and 19 MRI studies were available for volumetric analysis. Results from a linear regression model showed that patients have a significantly lower MVRD and cerebellar volume compared to controls (p < 0.001 and p < 0.001 respectively). There was a significant negative correlation between age and MVRD for patients (p = 0.014). The rate of cerebellar atrophy measured by the loss of MVRD and cerebellar volume per year was higher at early ages (r = -0.578, p = 0.012 and r = -0.323, p = 0.48 respectively), particularly in patients under 11 years (p = 0.004). There was a significant positive correlation between MVRD and cerebellar volume in PMM2-CDG patients (r = 0.669, p = 0.001).

Conclusions: Our study quantifies a progression of cerebellar atrophy in PMM2-CDG patients, particularly during the first decade of life, and suggests a simple and reliable measure, the MVRD, to monitor cerebellar atrophy. Quantitative measurement of MVRD and cerebellar volume are essential for correlation with phenotype and outcome, natural follow-up, and monitoring in view of potential therapies in children with PMM2-CDG.

Citing Articles

Glycosylation and behavioral symptoms in neurological disorders.

Pradeep P, Kang H, Lee B Transl Psychiatry. 2023; 13(1):154.

PMID: 37156804 PMC: 10167254. DOI: 10.1038/s41398-023-02446-x.


[Advances in the diagnosis and treatment of phosphomannomutase 2 deficiency].

Zhou S Zhongguo Dang Dai Er Ke Za Zhi. 2023; 25(2):223-228.

PMID: 36854702 PMC: 9979379. DOI: 10.7499/j.issn.1008-8830.2209049.


Protein misfolding and clearance in the pathogenesis of a new infantile onset ataxia caused by mutations in PRDX3.

Martinez-Rubio D, Rodriguez-Prieto A, Sancho P, Navarro-Gonzalez C, Gorria-Redondo N, Miquel-Leal J Hum Mol Genet. 2022; 31(22):3897-3913.

PMID: 35766882 PMC: 9652108. DOI: 10.1093/hmg/ddac146.


Stroke-Like Episodes in PMM2-CDG: When the Lack of Other Evidence Is the Only Evidence.

Serrano M Front Pediatr. 2021; 9:717864.

PMID: 34708008 PMC: 8542667. DOI: 10.3389/fped.2021.717864.


Mutations Causing Early Onset Ataxia: Profiling Clinical, Dysmorphic and Structural-Functional Findings.

Martinez-Monseny A, Edo A, Casas-Alba D, Izquierdo-Serra M, Bolasell M, Conejo D Int J Mol Sci. 2021; 22(10).

PMID: 34068417 PMC: 8153625. DOI: 10.3390/ijms22105180.


References
1.
Antoun H, Villeneuve N, Gelot A, Panisset S, Adamsbaum C . Cerebellar atrophy: an important feature of carbohydrate deficient glycoprotein syndrome type 1. Pediatr Radiol. 1999; 29(3):194-8. DOI: 10.1007/s002470050571. View

2.
Lukas C, Bellenberg B, Koster O, Greschner S, Hahn H . A new sulcus-corrected approach for assessing cerebellar volume in spinocerebellar ataxia. Psychiatry Res. 2011; 193(2):123-30. DOI: 10.1016/j.pscychresns.2011.01.008. View

3.
Serrano M, De Diego V, Muchart J, Cuadras D, Felipe A, Macaya A . Phosphomannomutase deficiency (PMM2-CDG): ataxia and cerebellar assessment. Orphanet J Rare Dis. 2015; 10:138. PMC: 4623922. DOI: 10.1186/s13023-015-0358-y. View

4.
Eichler L, Bellenberg B, Hahn H, Koster O, Schols L, Lukas C . Quantitative assessment of brain stem and cerebellar atrophy in spinocerebellar ataxia types 3 and 6: impact on clinical status. AJNR Am J Neuroradiol. 2011; 32(5):890-7. PMC: 7965570. DOI: 10.3174/ajnr.A2387. View

5.
Aronica E, van Kempen A, van der Heide M, Poll-The B, van Slooten H, Troost D . Congenital disorder of glycosylation type Ia: a clinicopathological report of a newborn infant with cerebellar pathology. Acta Neuropathol. 2005; 109(4):433-42. DOI: 10.1007/s00401-004-0975-3. View